# OnCo record opb-201 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/opb-201/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "opb-201" ;
  schema:name "OPB-201"@en ;
  schema:description "OPB-201 is an experimental autologous TCR T-cell therapy from Outpace Bio, in phase 1 trials for recurrent endometrial cancer, platinum-resistant ovarian cancer and other solid tumours."@en ;
  schema:url <https://onco.cc/drugs/opb-201/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://outpacebio.com/our-science>, <https://clinicaltrials.gov/api/v2/studies/NCT07664735>, <https://clinicaltrials.gov/search?intr=OPB-201> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Autologous TCR T-cell therapy" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/prame/> ;
  onco:companies <https://onco.cc/companies/outpace-bio/> ;
  onco:trials <https://onco.cc/trials/nct07664735/> .